https://bsky.app/profile/mrlconsortium.bsky.socialhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3mgmy5cryic2xNew results from the UNITED trial: smallmargin, weekly adaptive MRlinac treatment for glioblastoma significantly cuts normal brain dose (V60Gy ↓ from 146 - 157 → 84 - 93 cm³) and lowers brainstem/optic chiasm dose while maintaining target coverage. https://www.sciencedirect.com/science/article/pii/S036030162600404909 Mar 2026 13:39 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mgmy5cryic2xhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3mg36baai222dRegistrations are now open for our upcoming Consortium Knowledge Exchange webinar! Georgios Tsekas from the NKI, presents Direct-to-treatment MRI-guided prostate RT using a generic patient-agnostic reference plan. Register on the MR-Linac Consortium Member Portal. #ProgressThroughCollaboration02 Mar 2026 11:40 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mg36baai222dhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3mftibdu5vk2eThere is still time to enter the MRgRT Spotlight competition! Don't miss out! https://members.mrlconsortium.org/event/mr-linac-consortium-mrgrt-spotlight-competition/ #ProgressThroughCollaboration27 Feb 2026 10:18 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mftibdu5vk2ehttps://bsky.app/profile/mrlconsortium.bsky.social/post/3meyal7jpgs2vBehind the MR‑Linac Consortium's progress is a group dedicated to advancing what’s possible in cancer care. The Clinical Steering Committee drives research focus, quality excellence, and global collaboration—fueling the rapid expansion of MR‑guided radiotherapy and improving outcomes for patients.16 Feb 2026 14:18 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3meyal7jpgs2vhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3meinafrwls24Registrations are now open for our upcoming Consortium Knowledge Exchange webinar! We welcome Clement Chevillard and Vincent Domec from Hôpital René Huguenin – Institut Curie, France, who will present on their experience integrating the Elekta Unity into a mixed vendor environment.10 Feb 2026 09:22 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3meinafrwls24https://bsky.app/profile/mrlconsortium.bsky.social/post/3mdv7atcns22dRegistrations are now open for our upcoming Consortium Knowledge Exchange webinar! We welcome Clement Chevillard and Vincent Domec from Hôpital René Huguenin – Institut Curie, France, who will present on their experience integrating the Elekta Unity into a mixed vendor environment.02 Feb 2026 15:51 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mdv7atcns22dhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3mdfouonhbc2uAbstract submissions for the MR‑Linac Consortium Meeting 2026 are now open! We welcome your research and insights as we prepare for an exciting gathering in Montreal. Submit your abstract today via the link in your emails or on the member portal. lnkd.in/ef3TrgGS #ProgressThroughCollaboration27 Jan 2026 11:48 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mdfouonhbc2uhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3mbo4pbqllc2aReady to spotlight your expertise in MR-guided Radiotherapy (MRgRT)? We’re looking for standout content: creative media, inspiring clinical cases, and innovative approaches that highlight the real impact of MRgRT in transforming treatment. 💡 Submit your entry today! lnkd.in/e3cc6-2k05 Jan 2026 09:27 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3mbo4pbqllc2ahttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m7zm3ou5d22zRadiographer-led adaptive #MRgRT workflows are reshaping radiotherapy, streamlining processes, and improving patient experience. Hear Charlie Tran from GenesisCare Australia : lnkd.in/erTKBt6C #ProgressThroughCollaboration mrlconsortium.org https://lnkd.in/erTKBt6C15 Dec 2025 12:11 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m7zm3ou5d22zhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m6f3vde2w22u24 Nov 2025 15:03 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m6f3vde2w22uhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m5t2f2kof222Celebrating Global Collaboration in MR-Linac Research! The MR-Linac Consortium continues to thrive as a truly international community, united by a shared mission to advance precision radiation therapy. Don’t miss this conversation with Dr. Qian Peng, Radiation Oncologist in China: lnkd.in/eve3usMq https://lnkd.in/eve3usMq17 Nov 2025 10:48 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m5t2f2kof222https://bsky.app/profile/mrlconsortium.bsky.social/post/3m5ghwnwwqs2sAt the 20th Consortium meeting, it was inspiring to connect with so many members and see the progress being made in MRgRT. We're grateful to all who contributed their expertise and enthusiasm. Until next time!12 Nov 2025 10:46 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m5ghwnwwqs2shttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m52hpv2zz22kWe are thrilled that Rad Chat joined us at the MR-Linac Consortium meeting! Rad Chat is a multi award winning podcast, education and social media platform focusing on radiotherapy and oncology. Curious to hear what Consortium attendees shared with them. Listen here: radchat.transistor.fm/episodes07 Nov 2025 16:10 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m52hpv2zz22khttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m4zxpxatlk25Today we awarded the best clinical, technical and young investigator abstracts. Congrats to this year's winners: Julia Peltenburg and Marlies Nowee, Xiangyu Zhang and Tariq Lalmahomed for their work in motion management, prostate cancer QoL and liver oligometastases treatment.07 Nov 2025 11:24 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m4zxpxatlk25https://bsky.app/profile/mrlconsortium.bsky.social/post/3m4uwhipbbc25The MR-Linac Consortium meeting kicked off today with 300+ members focused on sharing clinical data, research and the future of MRgRT. Huge thanks to our 2025 Organization Committee and Clinical Steering Committee Chair, Dr. Alison Tree, for driving MR-adaptive forward.05 Nov 2025 11:18 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m4uwhipbbc25https://bsky.app/profile/mrlconsortium.bsky.social/post/3m3wj2stims2b📄 This MOMENTUM study highlights the safety and tolerability of MRI-guided SBRT for liver metastases, showing promising results in maintaining disease control with manageable side effects. Patients reported a stable quality of life throughout treatment. lnkd.in/eN8sEzmz #MOMENTUM #LiverCancer https://lnkd.in/eN8sEzmz24 Oct 2025 08:58 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m3wj2stims2bhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m3oyopsi3c2ywww.mrlconsortium.org #ProgressThroughCollaboration21 Oct 2025 09:16 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m3oyopsi3c2yhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m2oqfeljys2cResearch from UTSW explores how PSMA-PET imaging can guide adaptive SABR in high-risk prostate cancer—refining tumor boosts based on response, without adding treatment time. MR-Linac and CBCT systems can offer practical paths to personalized, biology-driven radiotherapy. lnkd.in/e4pHnZg2 https://lnkd.in/e4pHnZg208 Oct 2025 13:23 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m2oqfeljys2chttps://bsky.app/profile/mrlconsortium.bsky.social/post/3m2bqzdxsck2sWe’re thrilled to announce that the speaker lineup for the MR-Linac Consortium Meeting this November is confirmed! Last year’s meeting brought together brilliant minds, bold ideas, and transformative conversations in MR-guided radiotherapy and this year promises to be even more impactful.03 Oct 2025 09:29 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3m2bqzdxsck2shttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lzghbqvbi22dThis study explores the feasibility and early outcomes of MR-guided stereotactic ablative radiotherapy (MRgSTAR) for patients with synchronous oligometastatic prostate cancer (OMPC). ✅ 100% 3-year overall survival ✅ 95.2% progression-free survival https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1607610/full22 Sep 2025 12:53 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lzghbqvbi22dhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lywwfjpplc2416 Sep 2025 08:41 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lywwfjpplc24https://bsky.app/profile/mrlconsortium.bsky.social/post/3lykvu7z3vc2jThis retrospective analysis of five patients treated in the MOMENTUM study highlights that daily MR-adaptation reduces dose variability and OAR exposure compared to MR-guided plans alone for cervical cancer. #CervicalCancer #MOMENTUM https://medicaljournalssweden.se/actaoncologica/article/view/4289811 Sep 2025 14:00 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lykvu7z3vc2jhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lwr2j5pv3s2awww.mrlconosrtium.org19 Aug 2025 13:48 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lwr2j5pv3s2ahttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lweilwxxuk2g🚨A recent study leveraging MOMENTUM’s extensive dataset underlines that online adaptive MR-guided radiotherapy (MRgRT) shows promise for patients with non-metastatic pancreatic cancer. ✅ Maintained quality of life ✅ Significant symptom improvement at 6 months https://www.redjournal.org/article/S0360-3016(25)00307-4/abstract14 Aug 2025 13:56 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lweilwxxuk2ghttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lvqlgyuw4c25Advancing MR-Guided Radiotherapy in Esophageal Cancer A recent study from UMC Utrecht, explores the ATS-lite workflow—a simplified approach to online adaptive MRgRT which streamlines treatment delivery to a median of 23 minutes, while maintaining 90% target coverage. https://www.phiro.science/article/S2405-6316(25)00022-3/fulltext06 Aug 2025 15:54 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lvqlgyuw4c25https://bsky.app/profile/mrlconsortium.bsky.social/post/3lvdtufgkac2dResearchers in Nijmegen, Netherlands, have created an open-access online tool for early economic evaluation. This tool provides insights into the cost-effectiveness of MRIgRT. lnkd.in/e2sRxFRs Users can input their own data lnkd.in/erDkxXpF www.mrlconsortium.org hashtag#ProgressThroughCollaboration https://lnkd.in/e2sRxFRs01 Aug 2025 14:20 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lvdtufgkac2dhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lu5vooz2r22lwww.mrlconsortium.org #ProgressThroughCollaboration17 Jul 2025 12:11 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lu5vooz2r22lhttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lterxcnqxk2p🗓️Is it time to retire the PTV concept? In this article, members of the MR-Linac Consortium in the Netherlands discuss advancements in online adaptive radiation therapy (RT) and its implications for planning target volume margins. 📊 https://www.redjournal.org/article/S0360-3016(25)00092-6/abstract07 Jul 2025 12:28 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lterxcnqxk2phttps://bsky.app/profile/mrlconsortium.bsky.social/post/3lsbedr5lxk23This study from Brescia compared Elekta Unity with Accuray Radixact outcomes for oropharyngeal cancer treatment. It shows that daily ATS workflow for treatment is feasible and well-tolerated, with potential advantages compared to helical tomotherapy. https://www.ctro.science/article/S2405-6308(25)00040-0/fulltext23 Jun 2025 10:21 +0000at://did:plc:4a6hc3clhw4m5ebb5ax7djmi/app.bsky.feed.post/3lsbedr5lxk23